Titre (en)
Exploration
Accueil
Racine
Exploration
Accueil
Racine

Serveur d'exploration sur la maladie de Parkinson - Exploration (Accueil)

Index « Titre (en) » - entrée « dopa »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
door < dopa < dopamine  Facettes :

List of bibliographic references indexed by dopa

Number of relevant bibliographic references: 53.
[0-20] [0 - 20][0 - 50][20-40]
Ident.Authors (with country if any)Title
000141 (2011) Lynn Rochester [Royaume-Uni] ; Katherine Baker [Royaume-Uni] ; Alice Nieuwboer [Belgique] ; David Burn [Royaume-Uni]Targeting dopa‐sensitive and dopa‐resistant gait dysfunction in Parkinson's disease: Selective responses to internal and external cues
000408 (2011) Catherine L. Gallagher [États-Unis] ; Bradley T. Christian [États-Unis] ; James E. Holden [États-Unis] ; Onofre T. Dejesus [États-Unis] ; Robert J. Nickles [États-Unis] ; Laura Buyan-Dent [États-Unis] ; Barbara B. Bendlin [États-Unis] ; Sandra J. Harding [États-Unis] ; Charles K. Stone [États-Unis] ; Barb Mueller [États-Unis] ; Sterling C. Johnson [États-Unis]A within‐subject comparison of 6‐[18F]fluoro‐m‐tyrosine and 6‐[18F]fluoro‐L‐dopa in Parkinson's disease
000A57 (2009) Michael Niehues [Allemagne] ; Hensel [Allemagne]In‐vitro interaction of l‐dopa with bacterial adhesins of Helicobacter pylori: an explanation for clinicial differences in bioavailability?
000B43 (2009) A H Evans [Australie, Royaume-Uni] ; A D Lawrence [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni]Changes in psychomotor effects of L-dopa and methylphenidate after sustained dopaminergic therapy in Parkinson’s disease
000B79 (2009) Anna Brück [Finlande] ; Sargo Aalto [Finlande] ; Elina Rauhala [Finlande] ; Jörgen Bergman [Finlande] ; Reijo Marttila [Finlande] ; Juha O. Rinne [Finlande]A follow‐up study on 6‐[18F]fluoro‐L‐dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen
000D45 (2008) Peter Jenner [Royaume-Uni]Molecular mechanisms of L-DOPA-induced dyskinesia
001015 (2007) Stefano Zoccolella [Italie] ; Giovanni Iliceto [Italie] ; Michele Demari [Italie] ; Paolo Livrea [Italie] ; Paolo Lamberti [Italie]Management of L-Dopa related hyperhomocysteinemia: catechol-O-methyltransferase (COMT) inhibitors or B vitamins? Results from a review
001197 (2006) Anna L. Bartels [Pays-Bas] ; Bauke M. De Jong [Pays-Bas] ; Nir Giladi [Israël] ; Joanna D. Schaafsma [Pays-Bas] ; R. Paul Maguire [Pays-Bas] ; Lammy Veenma [Pays-Bas] ; Jan Pruim [Pays-Bas] ; Yacov Balash [Israël] ; Moussa B. H. Youdim [Israël] ; Klaus L. Leenders [Pays-Bas]Striatal dopa and glucose metabolism in PD patients with freezing of gait
001322 (2006) Olivier Rascol [France] ; David J. Brooks [Royaume-Uni] ; Amos D. Korczyn [Israël] ; Peter P. De Deyn [Belgique] ; Carl E. Clarke [Royaume-Uni] ; Anthony E. Lang [Canada] ; Mona Abdalla [Royaume-Uni]Development of dyskinesias in a 5‐year trial of ropinirole and L‐dopa
001412 (2005) Mariese A. Hely [Australie] ; John G. L. Morris [Australie] ; Wayne G. J. Reid [Australie] ; Robert Trafficante [Australie]Sydney multicenter study of Parkinson's disease: Non‐L‐dopa–responsive problems dominate at 15 years
001574 (2004) Fabio Guerini [Italie] ; Giovanni B. Frisoni [Italie] ; Catherine Bellwald [Italie] ; Roberta Rossi Psy [Italie] ; Giuseppe Bellelli [Italie] ; Marco Trabucchi [Italie]Subcortical Vascular Lesions Predict Functional Recovery After Rehabilitation in Patients with L‐Dopa Refractory Parkinsonism
001A22 (2001) Elina Nurmi [Finlande] ; Hanna M. Ruottinen [Finlande] ; Jörgen Bergman [Finlande] ; Merja Haaparanta [Finlande] ; Olof Solin [Finlande] ; Pirkko Sonninen [Finlande] ; Juha O. Rinne [Finlande]Rate of progression in Parkinson's disease: A 6‐[18F]fluoro‐L‐dopa PET study
001B10 (2001) P. K. Pal [Canada] ; C. S. Lee [Canada] ; A. Samii [Canada] ; M. Schulzer [Canada] ; A. J. Stoessl [Canada] ; E. K. Mak [Canada] ; J. Wudel [Canada] ; T. Dobko [Canada] ; J. K. C. Tsui [Canada]Alternating two finger tapping with contralateral activation is an objective measure of clinical severity in Parkinson's disease and correlates with PET [18F]-DOPA Ki
001C34 (2000) J. Lyytinen [Finlande] ; S. Kaakkola [Finlande] ; A. Gordin [Finlande] ; E.-R Kultalahti [Finlande] ; H. Ter V Inen [Finlande]Entacapone and selegiline with l-dopa in patients with Parkinson's disease: an interaction study
001D65 (1999) C. S. Biggs [Royaume-Uni] ; M. S. Starr [Royaume-Uni]Microdialysis study of the effects of the antiparkinsonian drug budipine on L‐DOPA‐induced release of dopamine and 5‐hydroxytryptamine by rat substantia nigra and corpus striatum
001D72 (1999) Taylor [Royaume-Uni] ; Beerahee [Royaume-Uni] ; Citerone [États-Unis] ; Cyronak [États-Unis] ; Leigh [Royaume-Uni] ; Fitzpatrick [Royaume-Uni] ; Lopez‐Gil [Royaume-Uni] ; Vakil [Royaume-Uni] ; Burns [Royaume-Uni] ; Lennox [Royaume-Uni]Lack of a Pharmacokinetic Interaction at Steady State Between Ropinirole and L‐Dopa in Patients with Parkinson's Disease
001D86 (1999) J. S. Rakshi ; T. Uema ; K. Ito ; D. L. Bailey ; P. K. Morrish ; J. Ashburner ; A. Dagher ; I. H. Jenkins ; K. J. Friston ; D. J. BrooksFrontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [18F]dopa-PET study
001E01 (1999) Yasushi Ito [Japon] ; Masahiro Fujita [Japon] ; Shoichi Shimada ; Yoshiyuki Watanabe [Japon] ; Tomoya Okada [Japon] ; Hideo Kusuoka [Japon] ; Masaya Tohyama [Japon] ; Tsunehiko Nishimura [Japon]Comparison between the decrease of dopamine transporter and that of L‐DOPA uptake for detection of early to advanced stage of Parkinson's disease in animal models
001E50 (1998) Mark D. Lindner [États-Unis] ; Dwaine F. Emerich [États-Unis]Therapeutic Potential of a Polymer-Encapsulated l-DOPA and Dopamine-Producing Cell Line in Rodent and Primate Models of Parkinson’s Disease
001E55 (1998) C. S. Biggs [Royaume-Uni] ; A. Fisher [Royaume-Uni] ; M. S. Starr [Royaume-Uni]The antiparkinsonian drug budipine stimulates the activity of aromatic L‐amino acid decarboxylase and enhances L‐DOPA‐induced dopamine release in rat substantia nigra
001F04 (1998) Jeon [Corée du Sud] ; Jae-Min Jeong [Corée du Sud] ; Sung-Sup Park [Corée du Sud] ; Jong-Min Kim [Corée du Sud] ; Young-Soo Chang [Corée du Sud] ; Ho-Chun Song [Corée du Sud] ; Kyeong-Min Kim [Corée du Sud] ; Keun-Young Yoon [Corée du Sud] ; Myung-Chul Lee [Corée du Sud] ; Sang-Bok Lee [Corée du Sud]Dopamine transporter density measured by [123I]β‐CIT single‐photon emission computed tomography is normal in dopa‐responsive dystonia

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Title.i -k "dopa" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Title.i  \
                -Sk "dopa" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    Title.i
   |clé=    dopa
}}
Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 18:06:51 2016. Site generation: Wed Mar 6 18:46:03 2024